Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupUrologic OncologyDiseaseLung Carcinoma, Non-Small CellSubgroupICD10C34.-MeSHSequenceChemotherapyChemo-substanceSacituzumab GovitecanChemo-substanceSacituzumab GovitecanChemo-substanceSacituzumab GovitecanChemo-substanceSacituzumab GovitecanNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimNo. Substances4Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaNeuropathyNeutropeniaPyrexia only studiesPublicationAuthorPaz-Ares LGDiseaseNSCLC, Stadium IV, Progress nach ciplatin- oder anti–PD-(L)1-haltiger TherapieOriginComplutense University and Ciberonc, Madrid, Spain, EVOKE-01 trialProtocols in Revision 1 protocol foundProtocols under revision.Sacituzumab Govitecan 10, Non-Small Cell Lung Cancer (PID2664 V1.0)
